A review of current diagnostic and treatment methods for key aldosterone-related diseases

¹ Henan International Joint Laboratory of Recombinant Pharmaceutical Protein Expression System, Xinxiang Medical University, Xinxiang 453003, Henan, China

² Zhengzhou Immuno Biotech Co., Ltd., Henan, China

GPD 2022, 1(2), 136 https://doi.org/10.36922/gpd.v1i2.136

Submitted: 15 June 2022 | Accepted: 12 September 2022 | Published: 3 October 2022

© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Aldosterone is a steroid hormone secreted from the adrenal cortex and metabolized primarily in the kidneys. It promotes sodium retention and potassium excretion. Most plasma aldosterone exists in free form, with a rapid turnover rate. The increased in aldosterone in the body may lead to various metabolic diseases, such as primary aldosteronism, diabetes, and chronic kidney disease. The clinical detection methods for aldosterone include radioimmunoassay, chemiluminescence immunoassay, and liquid chromatography tandem mass spectrometry (LC-MS/MS). In addition to addressing the issue of false negatives and false positives from cross-reaction in immunoassays, the advantages of high-throughput detection are reflected through the use of LC-MS/MS. Furthermore, there is also new progress in the development of a related mineralocorticoid receptor (MR) antagonist, from spironolactone to eplerenone, and to a third-generation MR antagonist, and finerenone, which has been approved by the United States Food and Drug Administration in 2021. The side effects of spironolactone and eplerenone can be overcome by finerenone, and the third-generation antagonist has shown significant effect in the treatment of chronic kidney disease associated with Type 2 diabetes. In this paper, aldosterone-related diseases, the clinical detection methods, and the corresponding treatment methods are discussed.

Keywords

Aldosterone

Primary aldosteronism

Liquid chromatography tandem mass spectrometry

Mineralocorticoid receptor antagonist

Funding

Basic Research Project of Henan Provincial Key Scientific Research Program

Conflict of interest

The authors declare no conflict of interest.

References

[1]

Wannachalee T, Turcu AF, 2021, Primary Aldosteronism: A Continuum from Normotension to Hypertension. Curr Cardiol Rep, 23(8): 105. https://doi.org/10.1007/s11886-021-01538-8

[2]

Knights KM, Winner LK, Elliot DJ, et al., 2009, Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol, 68(3): 402–412. https://doi.org/10.1111/j.1365-2125.2009.03469.x

[3]

Gideon A, Sauter C, Ehlert U, et al., 2021, Aldosterone hyperreactivity to acute psychosocial stress induction in men with essential hypertension. Horm Behav, 134: 105018. https://doi.org/10.1016/j.yhbeh.2021.105018

[4]

Ambroisine ML, Milliez P, Nehme J, et al., 2004, Aldosterone and anti-aldosterone effects in cardiovascular diseases and diabetic nephropathy. Diabetes Metab, 30(4): 311–318. https://doi.org/10.1016/s1262-3636(07)70122-2

[5]

Dooley R, Harvey BJ, Thomas W, 2012, Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol, 350(2): 223–234. https://doi.org/10.1016/j.mce.2011.07.019

[6]

Chen ZW, Tsai CH, Pan CT, et al., 2019, Endothelial dysfunction in primary aldosteronism. Int J Mol Sci, 20(20): 5214. https://doi.org/10.3390/ijms20205214

[7]

Yanan L, 2021, Value of parathyroid hormone level in differential diagnosis of patients with primary aldosteronism and nonfunctional adrenal tumors. J Chin Pla Postgrad Med Sch, 42(9): 913-917.

[8]

Tomilin VN, Pyrshev K, Khayyat NH, et al., 2021, With-no-lysine kinase 1 (WNK1) augments TRPV4 function in the aldosterone-sensitive distal nephron. Cells, 10(6): 1482. https://doi.org/10.3390/cells10061482

[9]

Yanai K, Ishibashi K, Morishita Y, 2021, Systematic review and meta-analysis of renin-angiotensin-aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease. Front Pharmacol, 12: 662544. https://doi.org/10.3389/fphar.2021.662544

[10]

Ting C, 2022, Correlation among systolic blood pressure load, renin-angiotensin-aldosterone system and cortisol in patients with salt-sensitive hypertensive. Chin J Evid Bases Cardiovasc Med, 14(1): 84-86.

[11]

Nianrong Z, 2021, Treatment of hypertension in diabetic patients. Chin J Clin, 49(12): 1399-1401.

[12]

Colussi G, Catena C, Lapenna R, et al., 2007, Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care, 30(9): 2349–2354. https://doi.org/10.2337/dc07-0525

[13]

Bakris GL, Agarwal R, Anker SD, et al., 2019, Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol, 50(5): 333–344. https://doi.org/10.1159/000503713

[14]

Briet M, Schiffrin EL, 2010, Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol, 6(5): 261–273. https://doi.org/10.1038/nrneph.2010.30

[15]

Tse LS, Liao PL, Tsai CH, et al., 2019, Glycemia lowering effect of an aqueous extract of Hedychium coronarium leaves in diabetic rodent models. Nutrients, 11(3): 629. https://doi.org/10.3390/nu11030629

[16]

Van der Heijden C, Smeets EM, Aarntzen EH, et al., 2020, Arterial wall inflammation and increased hematopoietic activity in patients with primary aldosteronism. J Clin Endocrinol Metab, 105(5): e1967–e1980. https://doi.org/10.1210/clinem/dgz306

[17]

Zhu Z, 2021, Causes and countermeasures of cardiovascular events in chronic kidney disease. Chin J Integr Trad Western Nephrol, 22(10): 847-853.

[18]

Berney M, Vakilzadeh N, Maillard M, et al., 2021, Bariatric surgery induces a differential effect on plasma aldosterone in comparison to dietary advice alone. Front Endocrinol (Lausanne), 12: 745045. https://doi.org/10.3389/fendo.2021.745045

[19]

Do Carmo JM, da Silva AA, Hall V, 2021, Impact of mineralocorticoid receptor and angiotensin II Type 1 receptor antagonism on blood pressure regulation in obese Zucker rats: Role of sex differences. Am J Hypertens, 34(9): 999–1005. https://doi.org/10.1093/ajh/hpaa170

[20]

Wang P, Luo C, Zhu D, et al., 2021, Pericardial adipose tissue-derived leptin promotes myocardial apoptosis in high-fat diet-induced obese rats through janus kinase 2/ reactive oxygen species/Na+/K+-ATPase signaling pathway. J Am Heart Assoc, 10(18): e021369. https://doi.org/10.1161/JAHA.121.021369

[21]

Kalil GZ, Haynes WG, 2012, Sympathetic nervous system in obesity-related hypertension: Mechanisms and clinical implications. Hypertens Res, 35(1): 4-16. https://doi.org/10.1038/hr.2011.173

[22]

Wang Y, Li CX, Lin YN, et al., 2021, The role of aldosterone in OSA and OSA-related hypertension. Front Endocrinol (Lausanne), 12: 801689. https://doi.org/10.3389/fendo.2021.801689

[23]

Lin X, Ullah MH, Wu X, et al., 2021, Cerebro-cardiovascular risk, target organ damage, and treatment outcomes in primary aldosteronism. Front Cardiovasc Med, 8: 798364. https://doi.org/10.3389/fcvm.2021.798364

[24]

Van der Heijden C, Horst RT, van den Munckhof IC, et al., 2020, Vasculometabolic and inflammatory effects of aldosterone in obesity. J Clin Endocrinol Metab, 105(8): 2719–2731. https://doi.org/10.1210/clinem/dgaa356

[25]

Morimoto R, Omata K, Ito S, et al., 2018, Progress in the management of primary aldosteronism. Am J Hypertens, 31(5): 522–531. https://doi.org/10.1093/ajh/hpy018

[26]

Shidlovskyi VO, Shidlovskyi OV, Tovkai OA, et al., 2019, Topical diagnosis and determination of the primary hyperaldosteronism variant. J Med Life, 12(4): 322–328. https://doi.org/10.25122/jml-2019-0072

[27]

Fenghua L, 2015, Evaluation of two plasma renin and aldosterone detection methods for screening efficiency of primary aldosteronism. Chin J Hyperten, 23(2): 150-153.

[28]

Yangning H, 2019, Comparison of the diagnostic effects of chemiluminescence and radioimmunoassay on primary aldosteronism. J Third Mil Med Univ, 41: 2080-2086.

[29]

Fengfan Z, 2019, On the consistency of different methods for detecting aldosterone concentration in blood. Chin J Endocrinol Metab, 35(11): 934-938.

[30]

Jing F, 2021, Screening value of urinary aldosterone concentration in primary aldosteronism and comparison of mass spectrometry and chemiluminescence detection. J Sun Yat Sen Univ, 41(4): 563–571.

[31]

Chenfei J, 2021, Advances in the application of liquid chromatography-tandem mass spectrometry in the detection of steroid hormones in CAH screening. Int J Lab Med, 42(7): 881–885.

[32]

Zi-yun C, 2021, Diagnostic value of liquid chromatography tandem mass spectrometry in primary aldosteronism. Chin Clin Med, 28(5): 858–863.

[33]

Pilz S, Keppel MH, Trummer C, et al., 2019, Diagnostic accuracy of the aldosterone-to-active renin ratio for detecting primary aldosteronism. J Endocr Soc, 3(9): 1748–1758. https://doi.org/10.1210/js.2019-00145

[34]

Chen F, Chen Z, Peng Y, et al., 2021, A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for simultaneous quantification of aldosterone, renin activity, and angiotensin II in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci, 1179: 122740. https://doi.org/10.1016/j.jchromb.2021.122740

[35]

Lingli W, 2020, Application status of mineralocorticoid receptor antagonists in refractory hypertension. Adv Cardiovasc Dis, 41(10): 1026–1030.

[36]

Junfeng X, 2019, Research progress of mineralocorticoid receptor antagonists. Chin J Gerontol, 34(3): 724–727.

[37]

Ping Z, 2019, Research Progress of Aldosterone Receptor Antagonists. Vol. 21. United States: Southwest Military Doctor, p.521–524.

[38]

Ying-ying W, 2020, Virtual screening of antagonists for mineralocorticoid receptor. Chin J N Drugs, 29(6): 655–61.

[39]

Yuan X, Wang X, Li X, et al., 2019, Aldosterone promotes renal interstitial fibrosis via the AIF1/AKT/mTOR signaling pathway. Mol Med Rep, 20(5): 4033–4044. https://doi.org/10.3892/mmr.2019.10680

[40]

Haitao Z, 2021, Clinical application of new mineralocorticoid receptor antagonists. Chin J Nephrol Dial Transplant, 30(5): 449–50.

[41]

Yujie MM, 2016, Nonsteroidal mineralocorticoid receptor antagonist finerenone. Modern Med Clin, 31(1): 111–115.

[42]

Stewart Coats AJ, Shewan L, 2015, Eplerenone’s role in the management of complex cardiovascular disorders. Int J Cardiol, 200: 1–2. https://doi.org/10.1016/j.ijcard.2015.05.128

Previous article in this issue

Next article in this issue

Gene & Protein in Disease, Electronic ISSN: 2811-003X Published by AccScience Publishing